The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

With a market cap of $64.8 billion, CVS Health Corporation (CVS) is a leading pharmacy innovation company providing a wide ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and ...

Patient Capital Management, a value investing firm, released its “Patient Capital Opportunity Equity Strategy” fourth quarter ...

The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...

For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.

CVS Health's poor 2024 performance was driven by ... PBMs and MA plans are core to the CVS Caremark and Aetna insurance segments. But will the rhetoric stick? PBMs are an easy target.

Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $68.07, accompanied by ...

CVS Health Corp. is a healthcare company in the U.S. that owns CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; Aetna, a health insurance provider, among many ...

Zydus Lifesciences announced that it has entered into an agreement with CVS Caremark, a CVS Health (CVS) company, to add Zituvio, Zituvimet and Zituvimet XR tablets to its template formulary.